Why so many small semaglutide trials recruiting right now?

NCT07401992 at 62 feels like a PK or tolerability study, not a big outcomes trial.

That's my read too. The 200 and 140 studies look more like dose-finding or formulation comparisons. The 609 one is the only one with real power.

Don't forget NCT02079870. Completed with 30 enrolled. Tiny, so probably not pivotal either.

Wait, NCT07011667 is the 609 one? Active but not recruiting sounds like a maintenance or extension study.

The maintenance/extension angle makes sense, but without posted results we're guessing. Are all of these even semaglutide monotherapy?

I'd bet at least one is oral. Rybelsus is in the section title, and oral PK studies tend to be small.

I pulled the registry pages last month. NCT07401992 and NCT06989203 both list recruiting, 62 and 140. NCT06897475 at 200. I didn't see head-to-head results posted for any of them, so I'm not sure how people are ranking them. The 609 study being active, not recruiting is the only one that looks like it might have enough for subgroup analysis. Still, enrollment size alone doesn't tell us endpoint.

Enrollment size is such a trap. A 30-person completed study can still be useful for safety signals.

True, but 30 is tiny for anything beyond tolerability. I wouldn't draw efficacy conclusions from it.

The regitsry entry. It says recruiting, 62 enrolled.

My bigger question is why several semaglutide trials are still recruiting when one 609-person study is already active, not recruiting. It could be different populations, different formulations, or just sponsors covering separate regulatory questions. The completed 30-person study doesn't help much either way. I'd want to see primary endpoints before calling any of these redundant.

Small N isn't redundant, it's usually about the endpoint. A 60-person study can carry a continuous measure like waist circumference or a DEXA scan fine, you just can't power it for something like a heart event. I got screened for one and they measured my waist three separate times in one visit, which tells you the whole study lives or dies on that number.

The clusters are probably staged, not redundant, the 140-person one reports first and sponsors design the 609-person one off it. Cheap way to de-risk. My own version of this was tracking: I logged everything for exactly nine days in January and then never opened the app again, so I'm impressed anyone tracks enrollment numbers for fun.

Half these NCT numbers feel like they're running in the same office park, honestly.

What I'd check is who's excluded. A lot of the newer ones won't take anyone who's been on a GLP-1 in the last 3-6 months, and some require a comorbidity, so two studies with the same drug can have completely different pools. Are you seeing the sleep apnea or pediatric ones in that list, or just the weight-only ones?

I've got about 380 weigh-ins in a spreadsheet and the scale flatlined for 19 straight days around the four-month mark while my waist dropped almost 2 inches in that same window, then the scale caught up in about a week and a half. If I'd been enrolled in an 8-week study I'd have looked like a non-responder; at 12 weeks, a partial responder. Same body, different endpoint window, which is why I don't think the small-n studies are automatically redundant — they might be pinning down when the signal actually shows up, and a tight 62-person window can do that faster than one big slow trial. The other thing my own data keeps telling me is that my worst weeks were never the holidays, they were the ones where I slept under 6 hours three nights in a row. Sleep and stress moved my scale way more than one hevy dinner ever did. So when I see a new listing I basically hunt for two things: is the primary measure weight only, or weight plus waist or body comp, and what's the assessment week. Some of these look like they're answering 'does it work' and others 'when does it show,' which are genuinely different questions. And I'll admit the dumbest confounder in my whole dataset was the two weeks I switched from morning weigh-ins to after work — water and food alone gave me a 3-4 lb swing that took me forever to catch.

I stopped trusing the scale the day my jeans fit before the number moved.

Weekends wreck my weekly average. Two restaurant meals and I'm up 3 lbs Monday, back down by Wednesday.

Honestly I'd flip the framing — the 62-person one might be the most interesting listing here, because a tight well-defined window tells you something a 609-person grab bag doesn't. Has anyone actually pulled the primary outcome measure and the assessment week off each listing side by side? That's the comparison I'd want before calling any of them redundant.

62 people is a pilot, not a trial. Reading through the writeup, that's just fishing for a signal so they can justify a bigger one later.

My sleep tracker has been a better predictor than my food log, which nobody warned me about. Two weeks of 5h40m average in March and I lost basically nothing, then I bumped to 7h15m and dropped 4 lbs in nine days without changing a thing I ate. I know that's probably water and cortisol, but it repeated again in April, so now I guard my bedtime like it's a prescription. Phone downstairs at 9:30, blackout curtains, the whole boring routine. My husband thinks I've joined a cult. The odd part is my appetite the next afternoon is noticeably smaller after a good night, so it's less magic and more that I stop grazing at 3pm. Still the only lifestyle lever that's actually shown up on the tape measure.

@relapse_ricky said: my appetite the next afternoon is noticeably smaller after a good night

That tracks with what I've watched happen to people. Unrelated but adjacent — I almost screened for one of those and what killed it wasn't the size, it was the exclusion list — no prior bariatric surgery, no sleep apnea diagnosis, A1c in a narrow band. A 62-person study and a 600-person study can be chasing the same question with wildly different people in the room. Enrollment number tells you more about site capacity than about the science.

Two sweaty gym sessions and my scale jumps 3 lbs, then it's gone by Wednesday. Water is so petty.

Not a researcher, but worth knowing: it's easy to burn a whole Sunday down this hole. The smaller studies skew single-center academic work with weird eligibility — one wanted a specific sleep apnea score, another was post-bariatric only. Different populations, not different drugs. The part people forget is how boring the honest yardstick is: waist at the navel, same morning every week. A 3.5-inch drop over 14 weeks tells you more than a 62-person study ever will.

Not a researcher either, but I poked at a few of those same NCTs and the primary outcomes looked pretty different: one was HbA1c change at 26 weeks, another was % weight change at 52 weeks, and a couple looked like PK/tolerability runs for oral vs injectable. That can make small N less redundant than it seems. I also daily-weigh and only trust my 7-day trend, so short-term trial endpoints always make me squint. Did you happen to filter by phase or population? Curious if the 62 and 140 are early-phase/mechanistic while the 609 is the bigger outcomes study.

I’ve been poking at the same registry and my hunch is endpoints, not just oral vs injectable. Filter by “primary outcome” and some small ones are powered for gastric emptying, body composition, or GI tolerability at 12 weeks, while the 609-person one looks like a registrational weight/A1c endpoint. That makes them seem redundant until you compare what they’re actually measuring. Sharp follow-up: does anyone know if any are sub-studies nested under the bigger trial? I check sponsor, phase, masking, and actual vs estimated enrollment before getting excited. Saves me from reading 40 pages of protocol.

The thing I’d check is the primary outcome, not enrollment. A 62-person study can still be useful if it’s mechanistic—DEXA/MRI for lean mass or visceral fat, or strength/function tests—while the bigger ones are powered for HbA1c or total weight. If they’re all just “percent

I’d sort them by primary endpoint and visit schedule, not size. Soe small ones are probably mechanistic—food-cue MRI, hunger/satiety surveys, body comp/muscle, or whether people can actually hit protein and fiber with chaotic family dinners. That’s not redundant even if the med looks similar. With two kids, frequent clinic visits would kill it for me way before enrollment numbers. Do any of those listings have behavioral support arms, or are they mostly med vs placebo?

I started sorting those by Phase and primary purpose. The smaller ones I checked were mostly Phase 2 or investigator-initiated, often layering a behavioral/app component or testing a combo, while the 609 study looked like confirmatory Phase 3. So the cluster reads more like a funnel than redundancy: small signal-finding first, bigger outcomes later. My sharp follow-up: are several of them listed under the same sponsor? If one company is running country-specific arms, that’s a different story than independent teams chasing different endpoints. I track daily and just watch my trend line, so I mostly ignore enrollment size and look at what each trial actually measures.

I keep a sheet of these like I do stock/prices, and the tell is usually phase + primary outcome, not N. The 609 one is probably the only one powered for a hard endpoint; the smaller ones tend to be Phase 2 signal-finding—body comp, tolerability, or maintenance after withdrawal. That’s not redundant, especially if route differs. My sharp question: are any of them withdrawal/maintenance designs? Those explain small N and a recruiting cluster way better than “another weight loss study.” If you post the primary outcome column for each NCT, I’ll help compare.

The tell is the primary outcome field, not the enrollment number. The small one I pulled up had tolerability/discontinuation as its primary at around 12 weeks, same sponsor as a bigger study — so it's basically a screening funnel for the real trial. The 609 one is looking at durability after withdrawal, which takes years and bodies. Small N plus short window means they're answering "can people stay on it," not "does it work." Honestly the more useful question. Anyone else notice these cluster by sponsor when you sort by lead org?

Tbh The tell is in the trial design fields, not the enrollment numbers: look at phase, sponsor, and whether enrollment is listed as actual vs estimated. A 62-person study with a biomarker or tolerability primary outcome is an early signal check, not a mini weight-loss trial. If one sponsor owns the cluster, it’s a pipeline matrix. If it’s scattered academics, it’s publishable niches. My sharp follow-up: do any of them list maintenance, withdrawal, or discontinuation as the primary purpose? That’s the only non-redundant reason I can see to run a small one right now. Otherwise, someone is just fishing.

Honestly, One thing I look at beyond the primary outcome is the registry’s “masking” and “primary purpose” fields. A lot of smaller studies are mechanistic add-ons: body-composition scans, resting energy expenditure, adherence, or maintenance after stopping. They look redundant by size but answer different questions. I’m in maintenance myself, so I care way more about lean mass and whether habits stick than another short scale-focused endpoint. Sharp question: do any of those NCTs list a parent trial, or the same sponsor/site cluster? That’s usually the tell it’s a sub-study rather than duplication.

I’d filter by phase, allocation, and endpoint type before calling them redundant. A 62-person study is usually Phase 1/2 or mechanistic—e.g., gastric emptying, ad libitum energy intake, MRI-PDFF, DEXA—not powered for weight difference. The 609-person one sounds like a Phase 3/outcomes or safety database. Also check comparator: placebo vs active vs open-label. Are any of these oral PK/food-effect or combination tolerability studies? That would explain the cluster without overlap. I track body comp/labs in a sheet, and those surrogate endpoints are exactly what small trials can move.

not a researcher but i went down the same rabbit hole after a 2am queue. one thing i didn't see mentioned: some smaller listings are flagged as decentralized / virtual visits and want app-based food logs or a run-in where you prove

Tbh I’ve been poking at the registry too, and the thing that jumps out to me is the run-in/randomized-withdrawal design in some smaller ones. The 62 or 140 may be just the open-label lead-in before a much smaller maintenance-randomization. I also scan secondaries for body composition/DEXA or appetite/food-noise scales, which need fewer people than a big weight-change trial. Does NCT07401992 list a withdrawal phase, or is it just single-arm? That would explain a lot of the apparent redundancy.

Night shifter here. I ignore enrollment size and read exclusions. Half these small ones aren't efficacy trials. They're recruiting narrow groups—sleep apnea, knee pain, liver fat, fertility—and often ban anyone who's already used weight-loss meds. So they're not competing with the big one. Different population, different question. I also check if they require a wearable or app logging. For night-shift folks, that can be brutal. If

i’m not a researcher either, but I noticed some of those small ones seem aimed at specific populations—like older adults or people with knee pain—rather than just more weight loss. If you click “primary purpose” and outcome measures, you can see whether they’re testing a delivery model (coaching, dietitian visits) or a functional endpoint like mobility or sleep. That’s what I’d check before calling them redundant. Weird question: are any tracking whether participants keep the cooking/walking habits after the study ends? That’s the part that matters in my empty-nester reboot.

one thing I’d check is the intervention column, not just the drug name. Several small ones I clicked were semaglutide plus a lifestyle/app/coaching arm, or testing maintenance after people stop. That changes the question from “does it work” to “does it stick” or “does support amplify it.” I’m not a researcher, just a tracker nerd—I log protein, steps, and hunger 1–10 daily. My own graph is way noisier than a 12-week trial, lol. Sharp question: do any of those list a primary endpoint besides % weight change, like appetite scores or body composition? If so, small N makes more sense.

I’ve been poking at the primary outcomes instead of enrollment. A bunch of the smaller ones seem to use mechanistic endpoints—DEXA/MRI body composition, gastric emptying, satiety scales—rather than just scale weight. So they might not be redundant; they’re answering “how” rather than “how much.” In the trials I’ve skimmed, though, I can’t always tell if the sponsor is academic or industry. Does anyone know if that split explains the cluster? That seems like the missing piece.

I’d add another lens: check the “Primary Outcome Measures” and whether it’s a withdrawal/maintenance design. Some studies give everyone the drug first, then randomize to continue vs stop — that answers durability, not just initial loss, so a smaller group can make sense. Also look at sponsor and duration. If the primary endpoint is liver fat, hunger score, or body composition rather than scale weight, they’re not redundant, just narrow. I weigh daily but only trust my 7-day trend, so I get how noisy short windows are. Are any

I’m not a researcher either, but the thing I’d compare is study duration and what the primary endpoint actually captures. A 62-person study with a 12-week endpoint is answering a different question from a 609-person one running a year. I keep weekly averages in a spreadsheet, so I tend to notice whether a trial is measuring maintenance after the study drug stops, body composition, or just scale weight. That can make several smaller studies feel less redundant. Do any of those listings show a co-primary endpoint, like weight plus a metabolic marker, or is it mostly tolerability?

Tbh daily weigher here—small trials are like my scale data: single readings are noisy, trend matters. I’d filter those NCTs by phase and primary outcome, not just size. A 62-person study often smells like PK/tolerability; 200/140 could be Phase 2 signal-finding; 609 sounds powered for a registration endpoint. Not redundant if the primary outcomes differ. Sharp follow-up: do any of the small ones list something like gastric emptying, HbA1c, or patient-reported tolerability as primary instead of weight? That’s usually the tell. Also check “actual” vs “estimated” enrollment—sometimes 62 is just the current snapshot, not the target.

I’m not a researcher, just a plateau veteran. The first thing I open now is primary outcome plus time frame. Several small studies aren’t really weight-loss trials—they’re mechanistic: hunger scales, body comp scans, liver fat, gastric emptying. 62 people is plenty for that, not for proving pounds lost. I also look at whether they’re studying maintenance after stopping vs active loss. That’s the question I care about. Are any of these powered for weight change, or are they just biomarker studies dressed up like the same old trial?